Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Kyunghee University Medical Center
Sponsor:
Collaborator:
Acupuncture and Meridian Science Research Center
Information provided by (Responsible Party):
Jae-Woo Park, Kyunghee University Medical Center
ClinicalTrials.gov Identifier:
NCT01921504
First received: August 7, 2013
Last updated: August 9, 2013
Last verified: August 2013
  Purpose

The aim of the study is to investigate the effect of acupuncture treatment on functional dyspepsia.


Condition Intervention
Functional Dyspepsia
Device: Acupuncture

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial

Resource links provided by NLM:


Further study details as provided by Kyunghee University Medical Center:

Primary Outcome Measures:
  • Proportion of responders [ Time Frame: Once in treatment period (4 wks) ] [ Designated as safety issue: No ]

    The proportion of patients who answer "Yes" to more than half of adequate relief questions in the treatment period.

    Patients are expected to report their response to the acupuncture treatment by answering the following question at each visit: "After the last visit, have you had adequate relief of your stomach pain or discomfort?" Questions will be asked at each visit during treatment period (Twice a week for 4 wks, total 8 times - 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 wks). Responders are defined as patients reporting adequate relief for at least 50% of the study period (more than 4 times of "Yes" to adequate relief question out of total 8 questions). The proportion of responder will be compared statistically between experimental group and no intervention group.



Secondary Outcome Measures:
  • Nepean Dyspepsia Index - Korean version (NDI-K) [ Time Frame: After treatment (4 wks) ] [ Designated as safety issue: No ]
    The Nepean Dyspepsia Index is a reliable and valid measure of quality of life in FD. The Nepean Dyspepsia Index originally contains 42 items designed to measure impairment of a subject's ability to engage in relevant aspects of their life because of dyspepsia. It was subsequently shortened to 25 items, yielding 5 sub-scales. NDI-K, validated in 2004 by Choi at al., made up of 2 sections which are about symptom-based questions and quality of life. In this trial, symptom-based questions, i.e. questions about period, severity and distressful degree of 15 symptoms, will be evaluated.

  • EuroQol-5 Dimension (EQ-5D) [ Time Frame: After treatment (4 wks) ] [ Designated as safety issue: No ]

    EQ-5D is a standardized instrument as a measure of health outcome. EQ-5D consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).

    First page is made up of 5 questions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each question has 3 levels: no problem, some problems, major problems.

    Second page consists of EQ VAS and its explanation. EQ VAS records the respondent's self-rated health on a vertical visual analogue scale where each endpoint is labelled either 'Best imaginable health state' and 'Worst imaginable health state'.


  • Functional Dyspepsia-Related Quality of Life (FD-QoL) Questionnaire [ Time Frame: After treatment (4 wks) ] [ Designated as safety issue: No ]
    The FD-QOL scale is a 21-item Likert-type questionnaire that can easily be completed within 5 min. Short administration time and high comprehensibility supports the feasibility of measuring health-related quality of life.

  • Beck's Depression Inventory (BDI) [ Time Frame: After treatment (4 wks) ] [ Designated as safety issue: No ]
    The Beck Depression Inventory (BDI), created by Dr. Aaron T. Beck, is a 21-question multiple-choice self-report inventory and one of the most widely used instruments for measuring the severity of depression.

  • The State-Trait Anxiety Inventory (STAI) [ Time Frame: After treatment (4 wks) ] [ Designated as safety issue: No ]
    The State-Trait Anxiety Inventory (STAI) is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis. The STAI measures two types of anxiety - state anxiety (anxiety triggered by a specific event), and trait anxiety (anxiety derived from personal characteristic). Higher scores are positively correlated with higher levels of anxiety.

  • Ghrelin hormone measurement (1. Total ghrelin, 2. Deacylated ghrelin) [ Time Frame: After treatment (4 wks) ] [ Designated as safety issue: No ]
    Ghrelin is a gut-derived peptide found in the stomach. It is known to play a role in the regulation of gastric motility and appetite.

  • Genotype analysis by Axiom® exome genotyping arrays [ Time Frame: First visit (0 wk) ] [ Designated as safety issue: No ]
    Genome-wide association study (GWAS)examines genetic variants in different individuals to see if any variant is associated with a trait. In this study, the GWAS is planned to elucidate any associations between genetic difference and response to acupuncture treatment in FD patients.


Estimated Enrollment: 76
Study Start Date: August 2013
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acupuncture
Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
Device: Acupuncture

Acupuncture treatment

  1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)
  2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea
Other Name: Acupuncture treatment
No Intervention: No treatment
The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.

Detailed Description:

Functional dyspepsia (FD) is a functional gastrointestinal disorder without any structural lesion. FD is claimed to affect 25% of the population in South Korea. Although conventional approaches based on current evidence such as proton pump inhibitor and prokinetic agents have been used, many FD patients turn to traditional Korean Medicine treatment largely due to the lack of satisfactory effect of these treatments.

Acupuncture treatment, one of the most sought therapeutic modalities in traditional Korean Medicine, has been commonly used for gastrointestinal disorders in Korea. However, the effect of acupuncture on FD has not been rigorously evaluated. In the present study, we will investigate whether 8 sessions of acupuncture treatment over 4 weeks, in comparison with no acupuncture treatment, i.e. waitlist-control, improve symptoms of FD. Outcome measures include proportion of responder, Korean version of Nepean Dyspepsia Index, EuroQol-5 Dimension, Functional Dyspepsia-Related Quality of Life, Beck's Depression Inventory, State-Trait Anxiety Inventory and ghrelin hormone. Genome-wide association study (GWAS) will be also conducted to elucidate any possible difference in genotype between responders and non-responders to acupuncture treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age of 18 ~ 75, with a elementary-school diploma or higher, should be able to read and write Korean
  • One who meet Rome III FD criteria* and has been suffering from FD for the last 3 months with symptom onset at least 6 months prior to diagnosis

    • One or more of the following:

      1. Bothersome postprandial fullness
      2. Early satiation
      3. Epigastric pain
      4. Epigastric burning
  • One who checks more than 4 points on visual analogue scale (VAS) for dyspeptic symptoms
  • One who has normal esophagogastroduodenoscopy results within a year and been diagnosed with FD by a specialist consultation
  • One who receives no other treatments during the study
  • One who voluntarily agrees with study protocol and signs an written informed consent

Exclusion Criteria:

  • One who has peptic ulcer or gastroesophageal reflux disease (GERD)
  • One who has obvious signs of irritable bowel syndrome (IBS)
  • One who has alarm symptoms (weight loss, black or tar stool, dysphagia)
  • One who has serious structural disease (disease of heart, lung, liver or kidney) or mental illness
  • One who has had surgery related with the gastrointestinal tract (Appendectomy more than 6 months ago is acceptable)
  • One who is pregnant or breastfeeding
  • One who is taking drugs which might affect gastrointestinal tract (Wash-out period: 2 weeks before participating in the trial)
  • One who is HIV-positive
  • One who has a problem of malabsorption or maldigestion
  • One who has difficulties in attending the trial or receiving treatments (e.g Paralysis, serious mental illness, dementia, drug addiction, busyness, severe disorder in vision or hearing, impossibility of visit, illiterate, etc.)
  • One who does not want to sign the informed consents
  • One who has clotting disorders or leukopenia, pace-maker, seizure disorders or is taking anticoagulant therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01921504

Contacts
Contact: Jae-Woo Park, KMD, PhD +82-2-440-6219 pjw2907@khu.ac.kr
Contact: Seok-Jae Ko, KMD, Doctor's course +82-2-440-6245 kokokoko119@hanmail.net

Locations
Korea, Republic of
Kyung Hee University Oriental Medicine Hospital Recruiting
Seoul, Dongdaemun-gu, Korea, Republic of, 130-872
Contact: Jin-sung Kim, KMD, PhD    +82 2 958 8895    oridoc@khu.ac.kr   
Principal Investigator: Jin-sung Kim, KMD, PhD         
Sub-Investigator: Ga-jin Han, KMD, M.S.         
Sub-Investigator: Ju-yeon Kim, KMD, M.S.         
Sub-Investigator: Kyung Kang, KMD, M.S.         
Sub-Investigator: Seung-won Jang, KMD, B.S.         
Sub-Investigator: Ji-young Son, KMD, B.S.         
Kyung Hee University Hospital at Gangdong Recruiting
Seoul, Gangdong-gu, Korea, Republic of, 130-701
Contact: Jae-Woo Park, KMD, PhD    +82 2 440 6219    pjw2907@khu.ac.kr   
Principal Investigator: Jae-Woo Park, KMD, PhD         
Sub-Investigator: Seok-Jae Ko, KMD, M.S.         
Sub-Investigator: Hyangsook Lee, KMD, PhD         
Sub-Investigator: Kwang-ro Ju, MD, PhD         
Sub-Investigator: Su Kang Kim, PhD         
Sub-Investigator: Hyunju Chung, PhD         
Sub-Investigator: Seul-Ki Kim, KMD, B.S.         
Sub-Investigator: Min-ji Kim, KMD, B.S.         
Sub-Investigator: Mi-Hee Lee         
Sponsors and Collaborators
Kyunghee University Medical Center
Acupuncture and Meridian Science Research Center
Investigators
Principal Investigator: Jae-woo Park, Doctor's degree Kyung Hee University Hospital at Gangdong, Seoul, Repulic of Korea
  More Information

Additional Information:
No publications provided by Kyunghee University Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jae-Woo Park, Associate Professor, Department of Korean Internal Medicine, Kyunghee University Medical Center
ClinicalTrials.gov Identifier: NCT01921504     History of Changes
Other Study ID Numbers: KHNMC-OH-IRB 2013-006
Study First Received: August 7, 2013
Last Updated: August 9, 2013
Health Authority: Korea: Food and Drug Administration

Keywords provided by Kyunghee University Medical Center:
Functional Dyspepsia
Acupuncture
Genotype
Ghrelin

Additional relevant MeSH terms:
Dyspepsia
Gastritis
Signs and Symptoms, Digestive
Signs and Symptoms
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases

ClinicalTrials.gov processed this record on August 27, 2014